XML 62 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies - Narrative (Details)
 1 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2024
USD ($)
investment
segment
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Number of operating segments | segment     1    
Number of reportable segments | segment     1    
Restricted cash     $ 104,215,000 $ 150,000 $ 0
Non-marketable equity and other investments     $ 16,100,000 8,600,000  
Impairment of other assets $ 7,000,000 $ 5,300,000   22,100,000  
Number of non-marketable equity security investments | investment     1    
Contract assets     $ 3,400,000 4,900,000  
Goodwill impairment     0    
Performance obligations satisfied in prior periods     35,300,000 14,200,000 8,800,000
Deferred revenue     41,600,000 22,900,000  
Deferred revenue long term     6,100,000 5,000,000.0  
Deferred revenue, revenue recognized       14,500,000 13,900,000
Advertising expense     $ 0 $ 0 $ 0
Minimum          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Intangible assets, useful life     6 years    
Minimum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Remaining performance obligation, expected recognition period     1 year    
Maximum          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Intangible assets, useful life     12 years    
Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Remaining performance obligation, expected recognition period     2 years    
TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc.          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Restricted cash     $ 103,600,000